Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research raised DBV TECHNOLOGIE/S from a hold rating to a buy rating and set a $10.00 price target for the company in a report on Wednesday, April 10th. JMP Securities reissued a buy rating and set a $20.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, Stifel Nicolaus reissued a hold rating and set a $10.00 target price on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the company. DBV TECHNOLOGIE/S presently has an average rating of Hold and an average target price of $14.67.
NASDAQ:DBVT opened at $8.15 on Friday. DBV TECHNOLOGIE/S has a one year low of $3.60 and a one year high of $25.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.30 and a current ratio of 3.34. The firm has a market capitalization of $484.34 million, a PE ratio of -2.40 and a beta of 1.98. The firm has a 50 day moving average of $9.13.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Featured Story: What is a conference call?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.